Abacavir fik markedsføringstilladelse under navnet Ziagen i 1999, og lamivudin fik markedsføringstilladelse under navnet Epivir i 1996.
Both active substances have been available in the European Union (EU) since the late 1990s: abacavir was granted marketing approval as Ziagen in 1999, and lamivudine was granted marketing authorisation as Epivir in 1996.